

Clinical Trial Protocol

Iranian Registry of Clinical Trials

09 Jul 2026

Treatment of macular edema secondary to central vein occlusion

Protocol summary

Summary

Eligible patients are submitted to a complete ophthalmological examination. Fluorescein angiogram and Optical Coherence Tomography (OCT) will be performed at predetermined frequency. Patients will be submitted to intravitreal injections of 1.25 mg of bevacizumab every five weeks until OCT central macular thickness is below 250 microns up to a limit of 6 consecutive injections. After normalization of CMT, patients will be submitted to a single session of argon green laser. Follow-up will be performed at a 5-week interval. Main purpose is visual acuity and OCT changes. Improvement is defined as VA gain of 2 or more lines of ETDRS letters. VA worsening is defined as VA drop of 2 or more ETDRS lines.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201011295270N1**
Registration date: **2010-12-01, 1389/09/10**
Registration timing: **registered_while_recruiting**

Last update:

Update count: **0**

Registration date

2010-12-01, 1389/09/10

Registrant information

Name

Arnaldo Bordon

Name of organization / entity

Banco de Olhos de Sorocaba

Country

Brazil

Phone

0055112127000

Email address

afbordon@terra.com.br

Recruitment status

Recruitment complete

Funding source

Self funding by the Banco de Olhos de Sorocaba (Sorocaba Eye Bank Hospital)

Expected recruitment start date

2010-10-01, 1389/07/09

Expected recruitment end date

2011-06-01, 1390/03/11

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Treatment of macular edema secondary to central vein occlusion

Public title

Treatment of macular edema secondary to central vein occlusion

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: Visual acuity equal or worse than 20/40 and equal or greater than 20/400; Minimum OCT central thickness of 250 microns Onset of central vein occlusion between three and 12 months. Visual acuity better than 20/40 on the other eye Exclusion criteria: neovascularization of the retina, optic disk, iris or angle. Uncontrolled glaucoma Intraocular surgery and/or injection of any medication in the past 3 months

Age

From **50 years** old to **100 years** old

Gender

Both

Phase

1

Groups that have been masked

No information

Sample size

Target sample size: 15

Randomization (investigator's opinion)

N/A

Randomization description**Blinding (investigator's opinion)**

Not blinded

Blinding description**Placebo**

Not used

Assignment

Single

Other design features**Secondary Ids****1****Registry name**

VEIN OCCLUSION STUDY

Secondary trial Id

035/2010

Registration date

2010-05-08, 1389/02/18

Ethics committees**1****Ethics committee****Name of ethics committee**

Hospital Oftalmologico de Sorocaba Ethics Committee

Street address

Rua Nabeck Shiroma, 210

City

Sorocaba

Postal code

18360

Approval date

2010-08-03, 1389/05/12

Ethics committee reference number

035/2010

Health conditions studied**1****Description of health condition studied**

central vein occlusion

ICD-10 code

H34.8

ICD-10 code description

Other retinal vascular occlusions

Primary outcomes**1****Description**

change of visual acuity

Timepoint

6 months

Method of measurement

ETDRS chart

Secondary outcomes**1****Description**

OCT (Optical Coherence Tomography) central macular thickness changes

Timepoint

6 months

Method of measurement

Stratus OCT

Intervention groups**1****Description**

Intravitreal injections of 1.25 mg of bevacizumab every five weeks until OCT central macular thickness is below 250 microns up to a limit of 6 consecutive injections. After normalization of CMT, patients will be submitted to a single session of argon green laser; No control

Category

Treatment - Drugs

Recruitment centers**1****Recruitment center****Name of recruitment center**

Hospital Oftalmologico de Sorocaba

Full name of responsible person

Suellen Fogaca

Street address

Rua Nabeck Shiroma, 210

City

Sorocaba

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Banco de Olhos de Sorocaba

Full name of responsible person

Edil Souza

Street address

Rua Nabeck Shiroma, 210

City

Sorocaba

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Banco de Olhos de Sorocaba

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact

Name of organization / entity

Hospital Oftalmologico de Sorocaba

Full name of responsible person

Janaina CR de Souza

Position

fellow of the retina service

Other areas of specialty/work

Street address

Rua Nabeck Shiroma, 210

City

Sorocaba

Province

Sao Paulo

Postal code

18360

Phone

00551132127000

Fax

Email

janamedsouza@ig.com.br

Web page address

www.bos.org.br

Person responsible for scientific inquiries

Contact

Name of organization / entity

Hospital Oftalmologico de Sorocaba

Full name of responsible person

Arnaldo F Bordon

Position

Head of the Retina and Vitreous Sector

Other areas of specialty/work

Street address

Rua Nabeck Shiroma, 210

City

Sorocaba

Province

Sao Paulo

Postal code

18360

Phone

00551532127000

Fax

00551131154344

Email

afbordon@terra.com.br

Web page address

www.bos.org.br

Person responsible for updating data

Contact

Name of organization / entity

Hospital Oftalmologico de Sorocaba

Full name of responsible person

Arnaldo F Bordon

Position

Head of the Retina and Vitreous Sector

Other areas of specialty/work

Street address

Rua Nabeck Shiroma, 210

City

Sorocaba

Province

Sao Paulo

Postal code

18360

Phone

00551132127000

Fax

00551131154344

Email

afbordon@terra.com.br

Web page address

www.bos.org.br

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty